Skip to content
Screener

Myriad Genetics MYGN Q3 2025 earnings

Reported November 3, 2025 · After market close

Revenue$205.7MMiss by $1.3M
EPS-$0.13Miss by $0.12
Revenue estimate$207.0M
EPS estimate-$0.01

Next report

Nov 2, 2026 (in a month)
Revenue estimate$191.4M
EPS estimate-$0.16

Financials

Q3 2025

Income statement

See full
Revenue$205.7M-3.6%
Gross profit$143.8M-4.0%
Operating income-$23.3M-16.5%
Net income-$27.4M-24.0%
EPS (diluted)-$0.29-20.8%

Balance sheet

See full
Cash & equivalents$154.8M+41.0%
Total debt$212.3M+48.4%
Total equity$372.8M-49.1%
Total assets$728.1M-32.7%

Cash flow

See full
Operating cash flow$21.1M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$672.71M-70.0%
Enterprise value$730.21M-67.9%
P/S0.8×-1.9×

Profitability

See full
Gross margin70.4%+1.2pp
Operating margin-51%-82.3pp
Net margin-48.5%-82.1pp

Returns & leverage

See full
Return on equity-72.5%-102pp
Debt / equity0.6×+0.4×
Current ratio2.3×+0.4×

FAQ

When did Myriad Genetics report Q3 2025 earnings?
Myriad Genetics (MYGN) reported Q3 2025 earnings on November 3, 2025 after market close.
What were Myriad Genetics's Q3 2025 revenue and EPS?
Myriad Genetics reported revenue of $205.7M and eps of $-0.13 for Q3 2025.
Did Myriad Genetics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $207.0M by $1.3M. EPS missed the consensus estimate of $-0.01 by $0.12.
How did Myriad Genetics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 3.6% from $213.3M a year earlier.
Where can I find Myriad Genetics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0000899923-25-000103) and the 10-Q periodic report (0000899923-25-000112) directly on SEC EDGAR. The filing index links above go to sec.gov.